As depicted in Figure 8, such nano-vaccines, co-delivering pathogen- or tumor-specific antigen and adjuvant, may address on one hand especially cDC2 via CR3, which at activated state stimulate antigen-specific CD4+ Th [74] and CD8+ T cells [75]. This evidence concerns the gene CD4 and neoplasm.